Befizal (Bezafibrate)

Befizal is indicated for the treatment of several lipid disorders where reduction of triglycerides and improvement of cholesterol profiles are desired.

• Patients with primary or secondary hyperlipidemia, especially those with markedly elevated triglyceride concentrations.
• Individuals diagnosed with hypertriglyceridemia, including cases where triglyceride levels exceed 200 mg/dL and pose a risk for pancreatitis.
• People with mixed dyslipidemia characterized by high low‑density lipoprotein (LDL) cholesterol together with elevated triglycerides.
• Patients who have not achieved target lipid levels through dietary modification, exercise, or other non‑pharmacologic measures alone.
• Use as part of a comprehensive cardiovascular risk‑reduction strategy in conjunction with statins or other lipid‑lowering agents, when clinically appropriate.

The safety profile of Befizal reflects the typical adverse events observed with fibrate therapy; most are mild and reversible, while rare serious reactions may occur.

Common

• Gastrointestinal discomfort such as nausea, abdominal pain, or dyspepsia.
• Muscle aches or mild myalgia without significant weakness.
• Elevated liver enzymes (transaminases) that are usually transient.
• Headache or dizziness.

Serious

• Myopathy or rhabdomyolysis, particularly when combined with statins.
• Severe liver injury presenting as jaundice or marked enzyme elevation.
• Acute renal failure or worsening of pre‑existing kidney disease.
• Allergic reactions including rash, pruritus, or angioedema.

Before initiating Befizal, clinicians should evaluate several clinical factors to minimize risk and ensure appropriate use.

• Assess baseline liver function tests; avoid use in patients with active hepatic disease.
• Review renal function; dose adjustment may be needed in moderate to severe impairment.
• Screen for a history of gallstones, as fibrates can increase biliary cholesterol saturation.
• Evaluate for concurrent use of statins or other myotoxic drugs, monitoring for muscle toxicity.
• Consider pregnancy and lactation status; safety data are limited, and use is generally avoided.
• Monitor lipid panels and liver enzymes periodically during therapy.
• Counsel patients on adhering to a low‑fat diet and avoiding excessive alcohol.

Befizal can affect the metabolism of other medicines; certain combinations should be avoided, while others require careful monitoring.

Avoid

• Concurrent use with strong CYP2C8 inhibitors (e.g., gemfibrozil) due to increased risk of myopathy.
• Co‑administration with high‑dose statins (especially simvastatin) that raises the likelihood of rhabdomyolysis.
• Combination with anticoagulants such as warfarin without dose adjustment, as fibrates may enhance anticoagulant effect.

Use with caution

• Concurrent therapy with other lipid‑lowering agents (e.g., niacin) may increase hepatic enzyme elevations.
• Use alongside nephrotoxic drugs (e.g., NSAIDs, aminoglycosides) in patients with reduced renal function.
• Combination with oral hypoglycemic agents may affect blood glucose control; monitor glycemic parameters.